Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS

Bioanalysis

Volumn 7, Issue 6, 2015, Pages 685-700

  Zhao, Ying Yong ^a   Tang, Dan Dan ^a   Chen, Hua ^a   Mao, Jia Rong ^b   Bai, Xu ^d   Cheng, Xiao Hong ^b   Xiao, Xin Yue ^c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Second Affiliated Hospital of Shaanxi University of Chinese Medicine   (China)

^c Waters Technologies Shanghai Ltd   (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITIC ACID; ALLANTOIN; ARISTOLOCHIC ACID; BIOLOGICAL MARKER; CHOLIC ACID; CITRIC ACID; CREATININE; FUMARIC ACID; GLUCOSE; HIPPURIC ACID; INDICAN; KYNURENIC ACID; SPERMINE; TAURINE; URIC ACID; AMINO ACID; ARISTOLOCHIC ACID I; BILE ACID; PURINE; PURINE DERIVATIVE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID SYNTHESIS; CITRIC ACID CYCLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; INTESTINE FLORA; MALE; METABOLITE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; PROTEIN URINE LEVEL; PURINE METABOLISM; QUADRUPOLE MASS SPECTROMETRY; RAT; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENERGY METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIPID PEROXIDATION; MASS SPECTROMETRY; METABOLISM; MULTIVARIATE ANALYSIS; PROCEDURES; REPRODUCIBILITY; URINALYSIS; URINE;

AMINO ACIDS; ANIMALS; ARISTOLOCHIC ACIDS; BILE ACIDS AND SALTS; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENERGY METABOLISM; GASTROINTESTINAL MICROBIOME; KIDNEY; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; PURINES; RATS; REPRODUCIBILITY OF RESULTS; URINALYSIS;

EID: 84928005291     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.309     Document Type: Article

References (49)

1. Xu EY, Schaefer WH, Xu Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr. Opin. Drug Discov. Devel. 12(1), 40-52 (2009).
2. Chen H, Miao H, Feng YL, Zhao YY, Lin RC. Metabolomics in dyslipidemia. Adv. Clin. Chem. 66, 101-119 (2014).
3. Zhao YY, Cheng XL, Vaziri ND, Liu S, Lin RC. UPLCbased metabonomics applications for discovering biomarkers of diseases in clinical chemistry. Clin. Biochem. 47(15), 16-26 (2014).
4. Zhao YY. Metabolomics in chronic kidney disease. Clin. Chim. Acta 422, 59-69 (2013).
5. Zhao YY, Lin RC. Metabolomics in nephrotoxicity. Adv. Clin. Chem. 65, 69-89 (2014).
6. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74(2), 158-169 (2008).
7. Cosyns JP, Dehoux JP, Guiot Y et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int. 59(6), 2164-2173 (2001).
8. Wang X, Sun H, Zhang A, Wang P, Han Y. Ultraperformance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. J. Sep. Sci. 34(24), 3451-3459 (2011).
9. Zhao YY, Wu SP, Liu S, Zhang Y, Lin RC. Ultraperformance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem. Biol. Interact. 220, 181-192 (2014).
10. Zhao YY, Lin RC. UPLC-MSE application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem. Biol. Interact. 215, 7-16 (2014).
11. Gao YL, Chen YP, Dong HR, Cong X. Experiment study on renal interstitial fibrosis of chronic aristolochic acid nephropathy in rats. Chin. J. Nephrol. 21(1), 31-35 (2005).
12. Zhao YY, Liu J, Cheng XL, Bai X, Lin RC. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin. Chim. Acta 413(5-6), 642-649 (2010).
13. Want EJ, Wilson ID, Gika H et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5(6), 1005-1018 2010.
14. Zhao YY, Cheng XL, Wei F, Bai X, Lin RC. Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MSE data collection technique. Biomarkers 17(8), 721-729 (2012).
15. Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O'Connor D. 'All-in-One' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun. Mass Spectrom. 19(18), 2597-602 (2005).
16. Zhao YY, Cheng XL, Wei F et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β1 mechanism in induced-adenine rats using UPLC Q-TOF/ HSMS/MSE. J. Proteome Res. 12(2), 692-703 (2013).
17. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 45(9), 1680-1688 (1994).
18. Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24(2), 172-180 (1994).
19. Li M, Wang X, Aa J et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 304(11), F1317-F1324 (2013).
20. Chuang CK, Lin SP, Chen HH et al. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis. Clin. Chim. Acta 364(1-2), 209-216 (2006).
21. Lenz EM, Bright J, Knight R et al. Metabonomics with 1H NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10(3), 173-187 (2005).
22. Sieber M, Hoffmann D, Adler M et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 109(2), 336-349 (2009).
23. Sato N, Takahashi D, Chen SM et al. Acute nephrotoxicity of aristolochic acids in mice. J. Pharm. Pharmacol. 56(2), 221-229 (2004).
24. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int. 52, S23-28 (1997).
25. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the proteinbound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 69(6), 1081-1087 (2006).
26. Lesaffer G, De Smet R, D'Heuvaert T, Belpaire FM, Lameire N, Vanholder R. Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. Kidney Int. 64(4), 1365-1373 (2003).
27. Meert N, Schepers E, Glorieux G et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol. Dial. Transplant. 27(6), 2388-2396 (2012).
28. Liabeuf S, Glorieux G, Lenglet A et al. Does P-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? Plos ONE 8(6), e67168 (2013).
29. Schefold J, Zeden J, Fotopoulou C et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serumlevels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uremic symptoms. Nephrol. Dial. Transplant. 24(6), 1901-1908 (2009).
30. Mohib K, Guan Q, Diao H, Du C. Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am. J. Physiol. 293(3), 1324-1329 (2007).
31. Zhao YY, Li HT, Feng YL, Bai X, Lin RC. Urinary metabonomic study of the surface layer of poria cocos as an effective treatment for chronic renal injury in rats. J. Ethnopharmacol. 148(2), 403-410 (2013).
32. Saito A, Takagi T, Chung TG, Ohta K. Serum levels of polyamines in patients with chronic renal failure. Kidney Int. 16, S234-S237 (1983).
33. Radtke HW, Rege AB, LaMarche MB et al. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J. Clin. Invest. 67(6), 1623-1629 (1981).
34. Igarashi K, Kashiwagi K. Use of polyamine metabolites as markers for stroke and renal failure. Methods Mol. Biol. 720, 395-408 (2011).
35. Cambell RA, Talwalkar Y, Bartos D et al. Polyamines, uremia and hemodialysis. Adv. Polyamine Res. 2, 319-343 (1978).
36. Chonchol M, Shlipak MG, Katz R et al. Relationship of uric acid with progression of kidney disease. Am. J. Kidney Dis. 50(2), 239-247 (2007).
37. Kastenbauer S, Koedel U, Becker BF, Pfister HW. Oxidative stress in bacterial meningitis in humans. Neurology 58(2), 186-191 (2002).
38. Matrens ME, Storey BT, Lee CP. Generation of allantoin from the oxidation of urate by cytochromec and its possible role in Reye's syndrome. Arch. Biochem. Biophys. 252(2), 91-96 (1987).
39. Roman K, Pavla Z. Allantoin as a marker of oxidative stress in human erythrocytes. Clin. Chem. Lab. Med. 46(9), 1270-1274 (2008).
40. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 62(3), 1060-1067 (2002).
41. Jiang L, Huang J, Wang Y, Tang H. Metabonomic analysis reveals the CCl4-induced systems alterations for multiple rat organs. J. Proteome Res. 11(7), 3848-3859 (2012).
42. Lv H, Liu L, Zhang Y, Song T, Lu J, Chen X. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol. Biosyst. 6(10), 2056-2067 (2010).
43. Zhao YY, Shen X, Cheng XL, Wei F, Bai X, Lin, RC. Urinary metabonomics study on the protective effects of ergosta-4,6,8(14),22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE data collection technique. Process Biochem. 47(12), 1980-1987 (2012).
44. Diercks DB, Owen K, Tolstikov V, Sutter M. Urinary metabolomic analysis for the identification of renal injury in patients with acute heart failure. Acad. Emerg. Med. 19(1), 18-23 (2012).
45. Domitrović R, Cvijanović O, Pugel EP, Zagorac GB, Mahmutefendić H, Škoda M. Luteolin ameliorates cisplatininduced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology 310(1), 115-123 (2013).
46. Sahin K, Tuzcu M, Gencoglu H et al. Epigallocatechin-3- gallate activates Nrf2/HO-1 signaling pathway in cisplatininduced nephrotoxicity in rats. Life Sci. 87(7-8), 240-245 (2010).
47. Chang J, Ma JZ, Zeng Q et al. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am. J. Physiol. Renal. Physiol. 304(4), F348-F355 (2103).
48. Takahashi T, Konta T, Takasaki S, Ichikawa K, Takeishi Y, Kubota I. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy. Clin. Exp. Nephrol. 11(3), 202-208 (2007).
49. Siems W, Carluccio F, Radenkovic S, Grune T, Hampl H. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res. 28(5-6), 295-301 (2005).